Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
In the latest session, Caris Life Sciences Inc (NASDAQ: CAI) closed at $36.5 down -1.32% from its previous closing price of $36.99. In other words, the price has decreased by -$1.32 from its previous closing price. On the day, 1.15 million shares were traded. CAI stock price reached its highest trading level at $38.3899 during the session, while it also had its lowest trading level at $35.64.
Ratios:
For a deeper understanding of Caris Life Sciences Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.60 and its Current Ratio is at 9.20. In the meantime, Its Debt-to-Equity ratio is 0.93 whereas as Long-Term Debt/Eq ratio is at 0.91.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wolfe Research on July 14, 2025, initiated with a Outperform rating and assigned the stock a target price of $32.
On July 14, 2025, TD Cowen started tracking the stock assigning a Buy rating and target price of $32.
On July 14, 2025, JP Morgan started tracking the stock assigning a Overweight rating and target price of $31.JP Morgan initiated its Overweight rating on July 14, 2025, with a $31 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jun 20 ’25 when Denton John Russel bought 7,500 shares for $21.00 per share. The transaction valued at 157,500 led to the insider holds 123,591 shares of the business.
Brille Brian J bought 30,000 shares of CAI for $630,000 on Jun 20 ’25. The insider now owns 162,428 shares after completing the transaction at $21.00 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CAI now has a Market Capitalization of 10266281984 and an Enterprise Value of 9962477568. For the stock, the TTM Price-to-Sale (P/S) ratio is 19.23 while its Price-to-Book (P/B) ratio in mrq is 22.67. Its current Enterprise Value per Revenue stands at 18.662 whereas that against EBITDA is -70.768.
Stock Price History:
Over the past 52 weeks, CAI has reached a high of $39.80, while it has fallen to a 52-week low of $25.40. The 50-Day Moving Average of the stock is 26.45%, while the 200-Day Moving Average is calculated to be 26.45%.
Shares Statistics:
For the past three months, CAI has traded an average of 1.20M shares per day and 861210 over the past ten days. A total of 281.22M shares are outstanding, with a floating share count of 114.28M. Insiders hold about 48.50% of the company’s shares, while institutions hold 10.20% stake in the company. Shares short for CAI as of 1753920000 were 1294477 with a Short Ratio of 1.08, compared to 1751241600 on 1360785. Therefore, it implies a Short% of Shares Outstanding of 1294477 and a Short% of Float of 0.9199999999999999.
Earnings Estimates
The company has 6 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is $0.02, with high estimates of $0.08 and low estimates of -$0.03.
Analysts are recommending an EPS of between -$0.85 and -$8.86 for the fiscal current year, implying an average EPS of -$2.52. EPS for the following year is $0.26, with 6.0 analysts recommending between $0.49 and -$0.05.
Revenue Estimates
For the next quarter, 7 analysts are estimating revenue of $205.37M. There is a high estimate of $214M for the next quarter, whereas the lowest estimate is $200.01M.
Based on 8 analysts’ estimates, the company’s revenue will be $977.6M in the next fiscal year. The high estimate is $1.01B and the low estimate is $955.4M.
